Abstract:Objective: Identifying minimal residual disease (MRD) in postoperative lung cancer patients is crucial for timely cancer intervention. However, current fixed panel methods suffer from low sensitivity, whereas personalized panels face challenges as long yield time and require patient tissue samples. Our objective was to develop an accurate and efficient method for detecting circulating-tumor DNA (ctDNA) in post-surgery lung cancer patients. Methods: The study retrospectively enrolled 39 lung cancer patients (14 relapse, 25 non-relapse) with 63 post-surgical plasma samples. The mutational profiles of cell-free DNA (cfDNA) were obtained using SHIELDINGTM ULTRA Panel by Geneseeq, covering hotspots in 2365 cancer-associated genes. A comprehensive error suppressing algorithm, which combines intra-run sampling adaptive noise control, cfDNA fragment profiling, normal pool, and white blood cell background, was utilized to eliminate the background artifacts. The plasma ctDNA status were identified under both tumor-informed and tumor-naïve scenarios. Results: Our method yielded results on par with personalized panels, achieving a sensitivity of 85.7% at the specificity of 92.0%, with a negative predictive value (NPV) of 92.0% in longitudinal analysis. The ctDNA positive patients had a 21-fold increased risk (Hazard Ratio [HR] = 20.7, p = 9.2 × 10^(-5)) compared to the ctDNA negative patients. Remarkably, the landmark analysis using 39 samples (⇐ 7 days post-surgical) showed a 57.1% sensitivity at 100.0% specificity. Patients with a landmark (⇐ 7 days post-surgical) ctDNA positive status showed an increased risk of 16.2 times (HR = 16.2, p = 3.5 × 10^(-6)). Furthermore, we found that our approach could maintain its level of performance under tumor-naïve scenario, showing HRs of 12.7 (p = 1.3 × 10^(-4)) for longitudinal ctDNA positive patients and 12.3 (p = 3.7 × 10^(-5)) for landmark ctDNA positive patients. The ctDNA status determined by the tumor-informed and tumor-naïve approaches showed a substantial agreement, yielding a concordance of 90.5% (Cohen's Kappa = 0.738). Conclusion: Herein, we report a comprehensive error suppressing approach for removing background artifacts by fixed MRD panel, allowing an enhanced MRD detection in post-surgical lung cancer patients. Our approach, which accurately identified ctDNA status at a cost-effective rate, outperformed other fixed panels while showing comparable performance with personalized panels. Furthermore, our method can be utilized under tumor naïve scenarios when personalized panels are unfeasible in the absence of tumor information. Finally, the faster turnout time of fixed panel makes our approach more suitable for clinical landmark MRD detection than a personalized panel. Citation Format: Hua Bao, Fanchen Meng, Zhijun Xia, Qinhong Sun, Siwei Wang, Wanxiangfu Tang, Ningyou Li, Min Wu, Jinfeng Zhang, Baihan Zhu, Dongqin Zhu, Xue Wu, Rong Yin, Yang Shao. Comprehensive error suppressing approach allowing enhanced minimal residual disease detection in lung cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3684.

Supplementary Data from Perioperative Ctdna-Based Molecular Residual Disease Detection for Non–Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)

Perioperative ctDNA-Based Molecular Residual Disease Detection for Non–Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)

Supplementary Data from Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer

Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Circulating Tumor DNA Clearance Predicts Prognosis Across Treatment Regimen in a Large Real-World Longitudinally Monitored Advanced Non-Small Cell Lung Cancer Cohort.

Postoperative Circulating Tumor DNA Can Refine Risk Stratification in Resectable Lung Cancer: Results from a Multicenter Study

Perioperative Ctdna-Based MRD Detection in NSCLC—Response

Supplementary Data from Genomic Landscape and Tumor Mutational Burden Determination of Circulating Tumor DNA in over 5,000 Chinese Patients with Lung Cancer

Dynamic ctDNA to inform the precise management of resected NSCLC: LUNGCA-2 study.

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

Multi-centre Clinical Study of Cell-Free DNA Mutations in Benign and Malignant Lung Lesions.

Table S1-2 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-Free DNA Fragmentomics

Association of Circulating Tumor DNA Clearance During Treatment with Improved Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients.

Supplementary Tables from The Open Chromatin Landscape of Non–Small Cell Lung Carcinoma

Abstract 3684: Comprehensive error suppressing approach allowing enhanced minimal residual disease detection in lung cancer patients

Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non–small cell lung cancer

Supplementary Figure S1 from Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer using Cell-Free DNA Fragmentomics

Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non–small cell lung cancers.

Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma

Adjuvant therapy-free strategy for Stage IB-IIIA Non-Small Cell Lung Cancer Patients after Radical Resection based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201)

Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non–Small-Cell Lung Cancer Patients after Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201)